- Open Access
Meta-analysis of glioblastoma multiforme versus anaplastic astrocytoma identifies robust gene markers
© Dreyfuss et al; licensee BioMed Central Ltd. 2009
- Received: 23 February 2009
- Accepted: 4 September 2009
- Published: 4 September 2009
Anaplastic astrocytoma (AA) and its more aggressive counterpart, glioblastoma multiforme (GBM), are the most common intrinsic brain tumors in adults and are almost universally fatal. A deeper understanding of the molecular relationship of these tumor types is necessary to derive insights into the diagnosis, prognosis, and treatment of gliomas. Although genomewide profiling of expression levels with microarrays can be used to identify differentially expressed genes between these tumor types, comparative studies so far have resulted in gene lists that show little overlap.
To achieve a more accurate and stable list of the differentially expressed genes and pathways between primary GBM and AA, we performed a meta-analysis using publicly available genome-scale mRNA data sets. There were four data sets with sufficiently large sample sizes of both GBMs and AAs, all of which coincidentally used human U133 platforms from Affymetrix, allowing for easier and more precise integration of data. After scoring genes and pathways within each data set, we combined the statistics across studies using the nonparametric rank sum method to identify the features that differentiate GBMs and AAs. We found >900 statistically significant probe sets after correction for multiple testing from the >22,000 tested. We also used the rank sum approach to select >20 significant Biocarta pathways after correction for multiple testing out of >175 pathways examined. The most significant pathway was the hypoxia-inducible factor (HIF) pathway. Our analysis suggests that many of the most statistically significant genes work together in a HIF1A/VEGF-regulated network to increase angiogenesis and invasion in GBM when compared to AA.
We have performed a meta-analysis of genome-scale mRNA expression data for 289 human malignant gliomas and have identified a list of >900 probe sets and >20 pathways that are significantly different between GBM and AA. These feature lists could be utilized to aid in diagnosis, prognosis, and grade reduction of high-grade gliomas and to identify genes that were not previously suspected of playing an important role in glioma biology. More generally, this approach suggests that combined analysis of existing data sets can reveal new insights and that the large amount of publicly available cancer data sets should be further utilized in a similar manner.
- Malignant Glioma
- Gene List
- Glioblastoma Multiforme
- Anaplastic Astrocytoma
- Feature List
High-grade gliomas, which include World Health Organization grade III astrocytomas (anaplastic astrocytoma: AA) and grade IV astrocytomas (glioblastoma multiforme: GBM), are the most common intrinsic brain tumors in adults and are almost universally fatal. GBMs are particularly invasive and aggressive. Patients diagnosed with GBM have a median survival time of one year , and less than 20% survive two years ; in contrast, the median survival for patients with AA is 30 months . Nearly all GBMs (>90%) are primary, i.e. they develop de novo with no evidence of a less malignant precursor lesion, whereas secondary GBMs develop from lower-grade astrocytomas . Histological criteria are currently the basis for tumor grading and prognosis, with GBM showing increased necrosis, vascular proliferation, nuclear pleomorphism, mitoses and invasiveness when compared to AA. The molecular basis for the histological and prognostic differences between grade III and grade IV astrocytomas remains an area of active investigation, e.g. one study found genes associated with necrosis in high-grade gliomas . A deeper understanding of the basis for these differences may lead to new therapeutic strategies for treating these tumors.
Differences in chromosomal alterations in AA and GBM have been described in several studies. For example, loss of heterozygosity for chromosome 10 was often observed in high-grade astrocytomas, and its frequency was found to be different between AA and GBM . Aberrations involving p53, EGFR, PTEN, and other genes have also been reported as having different frequencies in AA and GBM. Importantly, differences within the same grade were also observed. Aberrations on chromosome 10, for example, were found to be an independent, adverse prognostic marker for survival, even after accounting for age and grade [5, 6]. With the advent of microarrays, molecular portraits of these tumor grades were refined, and expression profiling was found to be a better predictor of outcome than histological criteria [7, 8]. These and other studies revealed the presence of molecular subgroups of malignant gliomas. One recent study identified three molecular subclasses of GBM that were characterized by proneural, proliferative, and mesenchymal mRNA expression signatures , and another isolated an expression signature that distinguished survival phenotypes .
Although a number of expression profiling studies have been performed on AA and GBM, they give conflicting results with regard to the list of relevant, differentially expressed genes between GBM and AA. This variability may be due to several factors. Most importantly, the sample sizes for these studies were relatively small due to the limited availability of suitable specimens and the significant costs associated with these studies. Other factors include differences in: the quality of the tissue specimens used (e.g. presence of non-tumor brain tissue or extensive necrosis), the microarray platforms used, the statistical methods employed to identify differentially expressed genes , and patient demographics such as age, gender, and race. Given the large number of factors that influence the list of differentially expressed genes, it is not surprising that gene lists from independent studies show little overlap. This lack of overlap has been observed in nearly all diseases in which microarrays have been employed, although the extent of the discrepancy depends on the heterogeneity of the disease .
To compile the most accurate and robust list of relevant genes, we performed a meta-analysis of multiple independent publicly available data sets, mostly from the Gene Expression Omnibus (GEO). GEO is the largest public repository of microarray data; it now contains over 250,000 samples and its size is rapidly increasing . While many of the published microarray data sets are centrally stored through GEO, the format and quality of the data sets are variable, and the annotations, both in terms of the probes on the platform and the sample phenotypes, are often incomplete. Thus, integrating information from these data sets requires significant bioinformatics analysis. In this study, many data sets were examined, and four data sets that satisfied our criteria for suitability in meta-analysis were selected. The resulting list of genes that are differentially expressed between AA and GBM is likely to be more robust and stable than that derived from any individual study to date.
Identification of appropriate data sets
To identify gene expression differences between AA and GBM, we searched GEO and many other databases containing publicly-available microarray data for data sets that contain information for both grades. One possible strategy for meta-analysis would have been to collect all data sets containing GBMs and all data sets containing AAs separately, and to then perform a single differential analysis. However, this could potentially lead to artifactual results due to methodological or technical differences among the studies, as mentioned above. Platform differences, for example, can have a significant influence on the results of microarray analyses. We have previously shown that even the differences arising from the use of successive generations of microarray platforms produced by the same company (e.g. Affymetrix) can be larger than the differences among patient samples . While such artifactual effects can be reduced somewhat with careful normalization and use of robust statistics, they cannot be eliminated. A more conservative approach is to combine the information obtained at the level of "within-experiment" gene lists, so that platform-specific and other biases are reduced.
Summary of the data sets
U133A and U133B
U133 plus 2.0
Mol Cancer Ther
Statistical approach to combining data sets
Analysis of differential expression in a single data set has been examined in great detail in the past decade [17, 18]. See  for a comparison of some commonly used methods. For this work, we focus on the methods for combining multiple data sets, i.e. for combining the scores of individual features across microarray experiments. Two classical statistical techniques that combine a feature's p-values directly are Fisher's method [19, 20], which relies on the sum of the logarithm of the p-values, and an alternative method proposed by Stouffer et al. (1949; cited in ), which transforms p-values into z-scores. Fisher's method was used, for instance, for analysis of microarray data on breast cancer , and both Fisher's and a weighted version of Stouffer's method were applied to study prostate cancer [23, 24]. Meta-analytic methods have also been developed specifically for genomics, many of which rely on traditional statistical approaches such as random effects [25, 26] and Bayesian modelling [27, 28], and some techniques have been advanced specifically for combining cancer microarray data . Meta-analysis for genomics has accrued so much literature that there is now a book dedicated to the topic .
Breitling et al. (2004) and Hong and Breitling (2007) have proposed a simple, intuitive method that evaluates genes based only on the product (or the sum) of its ranks [31, 32]. This method ranks each feature (such as a gene) within an experiment based on that feature's score (say, a t-statistic), and then combines these ranks, rather than combining the data or p-values themselves. For example, if a certain gene is the most differentially expressed gene in one experiment and is the tenth most differentially expressed gene in the three others, then its rank sum will be 1+10+10+10 = 31 and its rank product will be 1*10*10*10 = 1000, where the smaller is the rank sum or rank product, the more significant is the gene. The two approaches differ only in how they penalize the larger ranks; the rank product becomes very large even with a single high rank. Because rank-based procedures do not make assumptions about the model and parameters from which the data came, they are termed non-parametric.
We chose to use a rank-based method because: 1) in practice, the main purpose of microarray experiments is to rank genes rather than to obtain precise estimates of their statistical significance, since the number of statistically significant genes often greatly exceeds the number of genes that can be validated , 2) non-parametric analyses are more robust in general, 3) the techniques and assumptions used in the estimation of p-values and the subsequent correction for multiple hypothesis testing may be different between data sets and may not be directly comparable, and 4) using non-parametric methods to rank genes has proven highly effective in the context of genomics. Although more sophisticated rank-based procedures are available , the rank sum and rank product methods have been shown to give good results on microarray data . Because the rank sum technique is more robust than the rank product approach and is preferable when the variance of some features may be larger than others , we employ the rank sum procedure.
As a complement to the ordered gene list for each study, which we derive using moderated t-statistics , we also quantify differentially activated pathways between GBM and AA. The benefit of testing the significance of a priori defined gene sets (which correspond to pathways in this article) is that the recognition of such pathways may allow for better elucidation of the underlying biology, improved drug target development, and greater generalizability . In this work, we used a statistical method that we previously developed to identify significant gene sets while accounting for the differing sizes of gene sets and their correlation structure .
Meta-analysis gene list
Comparison of top genes
Meta Gene Name
glutamate dehydrogenase 1
glutamate dehydrogenase 2
chloride intracellular channel 1
collagen, type IV, alpha 1
coiled-coil domain containing 109B
vascular endothelial growth factor A
collagen, type IV, alpha 2
RAS-like, family 10, member A
insulin-like growth factor binding protein 2, 36kDa
protein phosphatase 2, regulatory subunit B', alpha isoform
proline/serine-rich coiled-coil 1
leucine zipper protein 2
ADP-ribosylation factor-like 4C
protein disulfide isomerase family A, member 4
cold shock domain containing C2, RNA binding
thymosin, beta 10
chitinase 3-like 1 (cartilage glycoprotein-39)
neuroepithelial cell transforming gene 1
melanoma cell adhesion molecule
lactate dehydrogenase A
collagen, type I, alpha 2
aldehyde dehydrogenase 2 family (mitochondrial)
collagen, type III, alpha 1 (Ehlers-Danlos syndrome type IV, autosomal dominant)
laminin, gamma 1 (formerly LAMB2)
solute carrier family 1 (glutamate/neutral amino acid transporter), member 4
Comparison to literature
Counts of relevant citations
# citations (PubMed)
% cited (PubMed)
% cited (Ingenuity)
The largest number of relevant citations derived from the top 30 genes of any single study is 128. To ensure that VEGFA does not dominate the comparison, we assigned it the same number of citations as the second best performing gene from all of Table 2 (which is SPP1, with 41 relevant citations). After this citation reduction for VEGFA, the meta-analysis list still generates 154 glioma/cancer/astrocytoma-related citations. The meta-analysis list's top 30 genes also have more citations related to the search term (22 genes) than any of the four studies. We further substantiated the results obtained from PubMed by evaluating these same gene lists using the manually curated Ingenuity Pathways Analysis software program (Ingenuity Systems, http://www.ingenuity.com). Ingenuity found that 60% of the top 30 unique genes from the meta-analysis have known connections to cancer, which is a 13% increase above the top-performing individual study.
Meta-analysis pathway list
Hypoxia-Inducible Factor in the Cardiovascular System
PKC-catalyzed phosphorylation of inhibitory phosphoprotein of myosin phosphatase
Vitamin C in the Brain
Adhesion Molecules on Lymphocyte
Nitric Oxide Signaling
Hypoxia and p53 in the Cardiovascular system
How does salmonella hijack a cell
Caspase Cascade in Apoptosis
Thrombin signaling and protease-activated receptors
Cell Cycle: G2/M Checkpoint
TSP-1 Induced Apoptosis in Microvascular Endothelial Cell
Y branching of actin filaments
Neutrophil and Its Surface Molecules
Role of BRCA1, BRCA2 and ATR in Cancer Susceptibility
Monocyte and its Surface Molecules
FAS signaling (CD95)
Regulation of PGC-1a
Cyclins and Cell Cycle Regulation
VEGF, Hypoxia, and Angiogenesis
Because it is not feasible to control for all the factors influencing gene expression in studies of human tumor specimens, it is important to aggregate as much high-quality data as possible to eliminate these sources of bias. Given the large volume of microarray data being generated by laboratories across the world, taking advantage of these data through meta-analysis has become a fruitful and inexpensive yet under-utilized approach. In our comparison of AA and GBM, including only four, albeit very large, studies does leave our results somewhat dependent on the quality of these microarray data sets. However, our methodology disfavors genes whose top ranks are not consistent. As future high-quality data sets become available, they can be incorporated into this framework to validate and improve the stability and accuracy of these results without the worry that such additions will lead to dramatic alterations in the ordering of features. Such benefits offer practical, concrete reasons for our choice of meta-analytic methodology and provide promising evidence for applying this analysis workflow to other pressing conditions.
Other similar studies may further benefit from using survival time as the phenotype of interest. Molecular signatures have been found to be better predictors of survival than histological grade in some cases [7, 8], i.e. the survival associated with tumors whose molecular profile was an "exception" to their histological grade was more strongly dictated by gene expression profile than by grade. However, Petalidis et al.  demonstrated that molecular signatures derived from histological grading of gliomas can be robust prognostic indicators whose accuracy in delineating survival subclasses may outperform classifiers trained on survival data, histological grade per se, and tumor subtypes defined by other studies. Nonetheless, meta-analyses that exploit survival data could potentially provide a more relevant list of candidate genes and a more powerful molecular classification of tumors. In this study, we had to restrict our focus to tumor grade because not all of our data sets had survival data available. This underscores the need for careful clinical annotation of the samples in these studies, even if a study does not involve survival analysis.
Although there is already a deep literature on the molecular properties of glioblastoma multiforme, The Cancer Genome Atlas project (TCGA) chose GBM as its first cancer to study . TCGA is an ongoing effort coordinated by the NIH in which numerous groups from many institutions collaboratively utilize the gamut of genome analysis technologies to accelerate our understanding of the molecular basis of cancer http://cancergenome.nih.gov/. It will be important to integrate our findings with those of TCGA (which compares GBM to normal tissue) and to identify pathways that are differentially expressed between GBM and AA with the hope of targeting these pathways therapeutically and increasing the survival of patients with GBM so that it approaches that of AA. Evidence that this approach is a useful one can be found in the fact that experimental and clinical studies have shown that agents that target the HIF1A/VEGF network can decrease tumor growth and prolong survival in both animals and humans [60, 61].
We have identified >900 probe sets and >20 pathways whose expression is statistically significantly different between GBM and AA. These feature lists are likely to be more accurate and stable because of the greater sensitivity and specificity that result from integration of data. Further, both the top genes and pathways implicate HIF1A/VEGF network activation as a major contributor to the increased growth and invasion displayed by GBM when compared to AA. The importance of these pathways is also evidenced by the utility of VEGF and HIF1A inhibitors in decreasing glioma growth and prolonging survival in vivo. This type of meta-analysis could be utilized to aid in the diagnosis and prognosis of malignant gliomas, and in the development of new therapies for these devastating tumors.
Data description and processing
Both the Human Genome U133A and U133B Affymetrix platforms contain >22,000 probe sets with no overlap between these two arrays. The Human Genome U133 Plus 2.0 array is composed of all of the probe sets on each of these two arrays as well as 9,921 new probe sets, giving it >54,000 probe sets in total. To accommodate all four of our studies, we used the 22,215 probe sets from the U133A array. Note that these are one-channel microarrays, so that only one sample is hybridized to each microarray. Hence, no controls were involved in our direct comparison of AAs to GBMs and there is no bias due to different controls used.
Petalidis et al. (2008) identified molecular signatures from primary human astrocytic tumors that define survival prognostic subclasses . Phillips et al. (2006) determined molecular subclasses of human gliomas useful in prediction of prognosis and disease progression . Sun et al. (2006) examined stem cell factor in primary human gliomas . Tso et al. (2006) identified glioblastoma associated genes in primary and secondary human gliomas  and deposited the data at UCLA: http://genomics.ctrl.ucla.edu/~snelson/PublicDATASETS/Tso_CancerResearch_2006/. Although the data set of Freije et al.  would have satisfied our criteria, its samples heavily overlap with those of Tso et al. .
Only the studies of Phillips et al.  and Tso et al.  had raw data (Affymetrix CEL) files available. We preprocessed these using RMA normalization  from the affy package , which is the same method employed by Petalidis et al. . Sun et al.  already applied the normalization procedure of Li and Wong . These differences in normalization technique, however, do not pose a hazard to this analysis due to our combination of "within-experiment" feature lists. All data was put on a log base 2 scale.
The implementation of the meta-analysis followed several steps. Firstly, features (either probe sets or pathways) were scored within each study. Secondly, features were ranked within each study by the magnitude (i.e. absolute value) of their respective statistic (say, a t-statistic), where the statistic closest to zero was given rank one, while that furthest from zero received the largest rank. Negative signs were then given to ranks corresponding to negative statistics to allow for asymmetric (i.e. if there are more upregulated than downregulated features, or vice versa) feature lists. Thirdly, a feature's ranks were summed across the four studies, assigning each feature a single rank sum. Lastly, these rank sums were compared to null ranks sums, derived by randomly permuting column labels and re-running the analysis, to obtain q-values. Note that according to this method, rank sums with larger magnitude are more significant.
To create per-study gene lists, we employed the empirical Bayes package limma , which offers a moderated t-statistic  for each gene, along with its associated p-value and conservatively estimated  q-value. The empirical Bayes methodology, and this package in particular, have been found in independent bioinformatics comparisons to be highly robust  and a preferred analysis method for Affymetrix GeneChips . Annotation was derived from the Affymetrix HG-U133A annotation files in CSV format, downloaded from NetAffx Analysis Center http://www.affymetrix.com/analysis.
Gene sets were derived from the Gene Set Enrichment Analysis (GSEA) Molecular Signature Database v2.5 , where we extracted Biocarta pathways from the "C2: curated gene sets" collection that hold between 20 and 500 genes. This gave 178 Biocarta pathways. Gene set elements were converted from gene symbols to U133A probe sets using GSEA's chip2chip tool [37, 69]. Analysis of gene sets was performed using our SigPathway Bioconductor package , which compares each gene set to a column and row permutation null distribution separately, giving two normalized enrichment scores per gene set. These enrichment scores were used separately for the column permutation and row permutation q-values in Additional file 2. Otherwise, within-experiment gene set rank was computed using the minimum (in magnitude) of these two scores for the overall q-value.
To compare the gene lists to the literature, we were able to automate our search of relevant citation counts for top genes by using the hgu133a package, which maps Affymetrix probe sets to Entrez Gene identifiers to PubMed identifiers, and the annotate package, which allows searching of PubMed abstracts. All statistical analysis was done in the R software  using packages from the Bioconductor project .
This work was supported by the National Center for Biomedical Computing grant (U54LM008748) to PJP, and the NIH Director's New Innovator Award (DP2OD002319) to MDJ.
- Lin C, Lieu A, Lee K, Yang Y, Kuo T, Hung M, Loh J, Yen C, Chang C, Howng S, Hwang S: The conditional probabilities of survival in patients with anaplastic astrocytoma or glioblastoma multiforme. Surg Neurol. 2003, 60: 402-406. discussion 406., 10.1016/S0090-3019(03)00322-7View ArticlePubMedGoogle Scholar
- Mischel P, Shai R, Shi T, Horvath S, Lu K, Choe G, Seligson D, Kremen T, Palotie A, Liau L, Cloughesy T, Nelson S: Identification of molecular subtypes of glioblastoma by gene expression profiling. Oncogene. 2003, 22: 2361-2373. 10.1038/sj.onc.1206344View ArticlePubMedGoogle Scholar
- Ohgaki H, Kleihues P: Genetic pathways to primary and secondary glioblastoma. Am J Pathol. 2007, 170: 1445-1453. 10.2353/ajpath.2007.070011PubMed CentralView ArticlePubMedGoogle Scholar
- Raza S, Fuller G, Rhee C, Huang S, Hess K, Zhang W, Sawaya R: Identification of necrosis-associated genes in glioblastoma by cDNA microarray analysis. Clin Cancer Res. 2004, 10: 212-221. 10.1158/1078-0432.CCR-0155-3View ArticlePubMedGoogle Scholar
- Balesaria S, Brock C, Bower M, Clark J, Nicholson S, Lewis P, de Sanctis S, Evans H, Peterson D, Mendoza N, Glaser M, Newlands E, Fisher R: Loss of chromosome 10 is an independent prognostic factor in high-grade gliomas. Br J Cancer. 1999, 81: 1371-1377. 10.1038/sj.bjc.6693403PubMed CentralView ArticlePubMedGoogle Scholar
- Burton E, Lamborn K, Feuerstein B, Prados M, Scott J, Forsyth P, Passe S, Jenkins R, Aldape K: Genetic aberrations defined by comparative genomic hybridization distinguish long-term from typical survivors of glioblastoma. Cancer Res. 2002, 62: 6205-6210.PubMedGoogle Scholar
- Freije W, Castro-Vargas F, Fang Z, Horvath S, Cloughesy T, Liau L, Mischel P, Nelson S: Gene expression profiling of gliomas strongly predicts survival. Cancer Res. 2004, 64: 6503-6510. 10.1158/0008-5472.CAN-04-0452View ArticlePubMedGoogle Scholar
- Nutt C, Mani D, Betensky R, Tamayo P, Cairncross J, Ladd C, Pohl U, Hartmann C, McLaughlin M, Batchelor T, Black P, von Deimling A, Pomeroy S, Golub T, Louis D: Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. Cancer Res. 2003, 63: 1602-1607.PubMedGoogle Scholar
- Phillips H, Kharbanda S, Chen R, Forrest W, Soriano R, Wu T, Misra A, Nigro J, Colman H, Soroceanu L, Williams P, Modrusan Z, Feuerstein B, Aldape K: Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell. 2006, 9: 157-173. 10.1016/j.ccr.2006.02.019View ArticlePubMedGoogle Scholar
- Marko N, Toms S, Barnett G, Weil R: Genomic expression patterns distinguish long-term from short-term glioblastoma survivors: a preliminary feasibility study. Genomics. 2008, 91: 395-406. 10.1016/j.ygeno.2008.01.002View ArticlePubMedGoogle Scholar
- Jeffery I, Higgins D, Culhane A: Comparison and evaluation of methods for generating differentially expressed gene lists from microarray data. BMC Bioinformatics. 2006, 7: 359- 10.1186/1471-2105-7-359PubMed CentralView ArticlePubMedGoogle Scholar
- Miklos G, Maleszka R: Microarray reality checks in the context of a complex disease. Nat Biotechnol. 2004, 22: 615-621. 10.1038/nbt965View ArticlePubMedGoogle Scholar
- Barrett T, Troup D, Wilhite S, Ledoux P, Rudnev D, Evangelista C, Kim I, Soboleva A, Tomashevsky M, Edgar R: NCBI GEO: mining tens of millions of expression profiles--database and tools update. Nucleic Acids Res. 2007, 35: D760-765. 10.1093/nar/gkl887PubMed CentralView ArticlePubMedGoogle Scholar
- Hwang K, Kong S, Greenberg S, Park P: Combining gene expression data from different generations of oligonucleotide arrays. BMC Bioinformatics. 2004, 5: 159- 10.1186/1471-2105-5-159PubMed CentralView ArticlePubMedGoogle Scholar
- Tso C, Freije W, Day A, Chen Z, Merriman B, Perlina A, Lee Y, Dia E, Yoshimoto K, Mischel P, Liau L, Cloughesy T, Nelson S: Distinct transcription profiles of primary and secondary glioblastoma subgroups. Cancer Res. 2006, 66: 159-167. 10.1158/0008-5472.CAN-05-0077View ArticlePubMedGoogle Scholar
- Bozinov O, Köhler S, Samans B, Benes L, Miller D, Ritter M, Sure U, Bertalanffy H: Candidate genes for the progression of malignant gliomas identified by microarray analysis. Neurosurg Rev. 2008, 31: 83-89. discussion 89-90., 10.1007/s10143-007-0107-3View ArticlePubMedGoogle Scholar
- Allison D, Cui X, Page G, Sabripour M: Microarray data analysis: from disarray to consolidation and consensus. Nat Rev Genet. 2006, 7: 55-65. 10.1038/nrg1749View ArticlePubMedGoogle Scholar
- Cui X, Churchill G: Statistical tests for differential expression in cDNA microarray experiments. Genome Biol. 2003, 4: 210- 10.1186/gb-2003-4-4-210PubMed CentralView ArticlePubMedGoogle Scholar
- Fisher R: Statistical Methods for Research Workers. 1932, Edinburgh: Oliver and Boyd, 4.Google Scholar
- Fisher R: Combining independent tests of significance. American Statistician. 1948, 2 (5): 30-10.2307/2681650. 10.2307/2681650Google Scholar
- Folks J: Combination of independent tests. 1984, New York: North-Holland.Google Scholar
- Smith D, Saetrom P, Snøve OJ, Lundberg C, Rivas G, Glackin C, Larson G: Meta-analysis of breast cancer microarray studies in conjunction with conserved cis-elements suggest patterns for coordinate regulation. BMC Bioinformatics. 2008, 9: 63- 10.1186/1471-2105-9-63PubMed CentralView ArticlePubMedGoogle Scholar
- Rhodes D, Barrette T, Rubin M, Ghosh D, Chinnaiyan A: Meta-analysis of microarrays: interstudy validation of gene expression profiles reveals pathway dysregulation in prostate cancer. Cancer Res. 2002, 62: 4427-4433.PubMedGoogle Scholar
- Setlur S, Royce T, Sboner A, Mosquera J, Demichelis F, Hofer M, Mertz K, Gerstein M, Rubin M: Integrative microarray analysis of pathways dysregulated in metastatic prostate cancer. Cancer Res. 2007, 67: 10296-10303. 10.1158/0008-5472.CAN-07-2173View ArticlePubMedGoogle Scholar
- Choi J, Yu U, Kim S, Yoo O: Combining multiple microarray studies and modeling interstudy variation. Bioinformatics. 2003, 19 (Suppl 1): i84-90. 10.1093/bioinformatics/btg1010View ArticlePubMedGoogle Scholar
- Stevens J, Doerge R: Meta-analysis combines affymetrix microarray results across laboratories. Comp Funct Genomics. 2005, 6: 116-122. 10.1002/cfg.460PubMed CentralView ArticlePubMedGoogle Scholar
- Wang J, Coombes K, Highsmith W, Keating M, Abruzzo L: Differences in gene expression between B-cell chronic lymphocytic leukemia and normal B cells: a meta-analysis of three microarray studies. Bioinformatics. 2004, 20: 3166-3178. 10.1093/bioinformatics/bth381View ArticlePubMedGoogle Scholar
- Jung Y, Oh M, Shin D, Kang S, Oh H: Identifying differentially expressed genes in meta-analysis via Bayesian model-based clustering. Biom J. 2006, 48: 435-450. 10.1002/bimj.200410230View ArticlePubMedGoogle Scholar
- Ma S, Huang J: Regularized gene selection in cancer microarray meta-analysis. BMC Bioinformatics. 2009, 10: 1- 10.1186/1471-2105-10-1PubMed CentralView ArticlePubMedGoogle Scholar
- Guerra R, Allison D, Goldstein D: Meta-analysis and Combining Information in Genetics and Genomics. 2009, Taylor & Francis, Inc.Google Scholar
- Breitling R, Armengaud P, Amtmann A, Herzyk P: Rank products: a simple, yet powerful, new method to detect differentially regulated genes in replicated microarray experiments. FEBS Lett. 2004, 573: 83-92. 10.1016/j.febslet.2004.07.055View ArticlePubMedGoogle Scholar
- Hong F, Breitling R: A comparison of meta-analysis methods for detecting differentially expressed genes in microarray experiments. Bioinformatics. 2008, 24: 374-382. 10.1093/bioinformatics/btm620View ArticlePubMedGoogle Scholar
- Smyth G, Yang Y, Speed T: Statistical issues in microarray data. Functional Genomics: Methods and Protocols. Edited by: Brownstein M, Khodursky A. 2003, 224: [Methods in Molecular Biology]., Totowa, NJ: Humana Press.View ArticleGoogle Scholar
- Zintzaras E, Ioannidis J: Meta-analysis for ranked discovery datasets: theoretical framework and empirical demonstration for microarrays. Comput Biol Chem. 2008, 32: 38-46. 10.1016/j.compbiolchem.2007.09.003View ArticlePubMedGoogle Scholar
- Breitling R, Herzyk P: Rank-based methods as a non-parametric alternative of the T-statistic for the analysis of biological microarray data. J Bioinform Comput Biol. 2005, 3: 1171-1189. 10.1142/S0219720005001442View ArticlePubMedGoogle Scholar
- Smyth G: Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol. 2004, 3: Article3.Google Scholar
- Mootha V, Lindgren C, Eriksson K, Subramanian A, Sihag S, Lehar J, Puigserver P, Carlsson E, Ridderstråle M, Laurila E, Houstis N, Daly M, Patterson N, Mesirov J, Golub T, Tamayo P, Spiegelman B, Lander E, Hirschhorn J, Altshuler D, Groop L: PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet. 2003, 34: 267-273. 10.1038/ng1180View ArticlePubMedGoogle Scholar
- Tian L, Greenberg S, Kong S, Altschuler J, Kohane I, Park P: Discovering statistically significant pathways in expression profiling studies. Proc Natl Acad Sci USA. 2005, 102: 13544-13549. 10.1073/pnas.0506577102PubMed CentralView ArticlePubMedGoogle Scholar
- Storey J, Tibshirani R: Statistical significance for genomewide studies. Proc Natl Acad Sci USA. 2003, 100: 9440-9445. 10.1073/pnas.1530509100PubMed CentralView ArticlePubMedGoogle Scholar
- Irizarry R, Warren D, Spencer F, Kim I, Biswal S, Frank B, Gabrielson E, Garcia J, Geoghegan J, Germino G, Griffin C, Hilmer S, Hoffman E, Jedlicka A, Kawasaki E, Martínez-Murillo F, Morsberger L, Lee H, Petersen D, Quackenbush J, Scott A, Wilson M, Yang Y, Ye S, Yu W: Multiple-laboratory comparison of microarray platforms. Nat Methods. 2005, 2: 345-350. 10.1038/nmeth756View ArticlePubMedGoogle Scholar
- Nigro J, Misra A, Zhang L, Smirnov I, Colman H, Griffin C, Ozburn N, Chen M, Pan E, Koul D, Yung W, Feuerstein B, Aldape K: Integrated array-comparative genomic hybridization and expression array profiles identify clinically relevant molecular subtypes of glioblastoma. Cancer Res. 2005, 65: 1678-1686. 10.1158/0008-5472.CAN-04-2921View ArticlePubMedGoogle Scholar
- Pelloski C, Mahajan A, Maor M, Chang E, Woo S, Gilbert M, Colman H, Yang H, Ledoux A, Blair H, Passe S, Jenkins R, Aldape K: YKL-40 expression is associated with poorer response to radiation and shorter overall survival in glioblastoma. Clin Cancer Res. 2005, 11: 3326-3334. 10.1158/1078-0432.CCR-04-1765View ArticlePubMedGoogle Scholar
- Castellani P, Borsi L, Carnemolla B, Birò A, Dorcaratto A, Viale G, Neri D, Zardi L: Differentiation between high- and low-grade astrocytoma using a human recombinant antibody to the extra domain-B of fibronectin. Am J Pathol. 2002, 161: 1695-1700.PubMed CentralView ArticlePubMedGoogle Scholar
- Liu C, Yao J, Mercola D, Adamson E: The transcription factor EGR-1 directly transactivates the fibronectin gene and enhances attachment of human glioblastoma cell line U251. J Biol Chem. 2000, 275: 20315-20323. 10.1074/jbc.M909046199View ArticlePubMedGoogle Scholar
- Kang M, Kang S: Pharmacologic blockade of chloride channel synergistically enhances apoptosis of chemotherapeutic drug-resistant cancer stem cells. Biochem Biophys Res Commun. 2008, 373: 539-544. 10.1016/j.bbrc.2008.06.070View ArticlePubMedGoogle Scholar
- Im S, Gomez-Manzano C, Fueyo J, Liu T, Ke L, Kim J, Lee H, Steck P, Kyritsis A, Yung W: Antiangiogenesis treatment for gliomas: transfer of antisense-vascular endothelial growth factor inhibits tumor growth in vivo. Cancer Res. 1999, 59: 895-900.PubMedGoogle Scholar
- Dunlap S, Celestino J, Wang H, Jiang R, Holland E, Fuller G, Zhang W: Insulin-like growth factor binding protein 2 promotes glioma development and progression. Proc Natl Acad Sci USA. 2007, 104: 11736-11741. 10.1073/pnas.0703145104PubMed CentralView ArticlePubMedGoogle Scholar
- Ouafik L, Sauze S, Boudouresque F, Chinot O, Delfino C, Fina F, Vuaroqueaux V, Dussert C, Palmari J, Dufour H, Grisoli F, Casellas P, Brünner N, Martin P: Neutralization of adrenomedullin inhibits the growth of human glioblastoma cell lines in vitro and suppresses tumor xenograft growth in vivo. Am J Pathol. 2002, 160: 1279-1292.PubMed CentralView ArticlePubMedGoogle Scholar
- Mahesparan R, Read T, Lund-Johansen M, Skaftnesmo K, Bjerkvig R, Engebraaten O: Expression of extracellular matrix components in a highly infiltrative in vivo glioma model. Acta Neuropathol. 2003, 105: 49-57.PubMedGoogle Scholar
- Forsythe J, Jiang B, Iyer N, Agani F, Leung S, Koos R, Semenza G: Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol. 1996, 16: 4604-4613.PubMed CentralPubMedGoogle Scholar
- Büchler P, Reber H, Büchler M, Shrinkante S, Büchler M, Friess H, Semenza G, Hines O: Hypoxia-inducible factor 1 regulates vascular endothelial growth factor expression in human pancreatic cancer. Pancreas. 2003, 26: 56-64. 10.1097/00006676-200301000-00010View ArticlePubMedGoogle Scholar
- Garayoa M, Martínez A, Lee S, Pío R, An W, Neckers L, Trepel J, Montuenga L, Ryan H, Johnson R, Gassmann M, Cuttitta F: Hypoxia-inducible factor-1 (HIF-1) up-regulates adrenomedullin expression in human tumor cell lines during oxygen deprivation: a possible promotion mechanism of carcinogenesis. Mol Endocrinol. 2000, 14: 848-862. 10.1210/me.14.6.848View ArticlePubMedGoogle Scholar
- Feldser D, Agani F, Iyer N, Pak B, Ferreira G, Semenza G: Reciprocal positive regulation of hypoxia-inducible factor 1alpha and insulin-like growth factor 2. Cancer Res. 1999, 59: 3915-3918.PubMedGoogle Scholar
- Semenza G, Jiang B, Leung S, Passantino R, Concordet J, Maire P, Giallongo A: Hypoxia response elements in the aldolase A, enolase 1, and lactate dehydrogenase A gene promoters contain essential binding sites for hypoxia-inducible factor 1. J Biol Chem. 1996, 271: 32529-32537. 10.1074/jbc.271.51.32529View ArticlePubMedGoogle Scholar
- Krishnamachary B, Berg-Dixon S, Kelly B, Agani F, Feldser D, Ferreira G, Iyer N, LaRusch J, Pak B, Taghavi P, Semenza G: Regulation of colon carcinoma cell invasion by hypoxia-inducible factor 1. Cancer Res. 2003, 63: 1138-1143.PubMedGoogle Scholar
- Infanger M, Grosse J, Westphal K, Leder A, Ulbrich C, Paul M, Grimm D: Vascular endothelial growth factor induces extracellular matrix proteins and osteopontin in the umbilical artery. Ann Vasc Surg. 2008, 22: 273-284. 10.1016/j.avsg.2007.11.002View ArticlePubMedGoogle Scholar
- Vasile E, Tomita Y, Brown L, Kocher O, Dvorak H: Differential expression of thymosin beta-10 by early passage and senescent vascular endothelium is modulated by VPF/VEGF: evidence for senescent endothelial cells in vivo at sites of atherosclerosis. FASEB J. 2001, 15: 458-466. 10.1096/fj.00-0051comView ArticlePubMedGoogle Scholar
- Petalidis L, Oulas A, Backlund M, Wayland M, Liu L, Plant K, Happerfield L, Freeman T, Poirazi P, Collins V: Improved grading and survival prediction of human astrocytic brain tumors by artificial neural network analysis of gene expression microarray data. Mol Cancer Ther. 2008, 7: 1013-1024. 10.1158/1535-7163.MCT-07-0177PubMed CentralView ArticlePubMedGoogle Scholar
- Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008, 455: 1061-1068.Google Scholar
- Jensen R, Ragel B, Whang K, Gillespie D: Inhibition of hypoxia inducible factor-1alpha (HIF-1alpha) decreases vascular endothelial growth factor (VEGF) secretion and tumor growth in malignant gliomas. J Neurooncol. 2006, 78: 233-247. 10.1007/s11060-005-9103-zView ArticlePubMedGoogle Scholar
- Vredenburgh J, Desjardins A, Herndon Jn, Dowell J, Reardon D, Quinn J, Rich J, Sathornsumetee S, Gururangan S, Wagner M, Bigner D, Friedman A, Friedman H: Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res. 2007, 13: 1253-1259. 10.1158/1078-0432.CCR-06-2309View ArticlePubMedGoogle Scholar
- Sun L, Hui A, Su Q, Vortmeyer A, Kotliarov Y, Pastorino S, Passaniti A, Menon J, Walling J, Bailey R, Rosenblum M, Mikkelsen T, Fine H: Neuronal and glioma-derived stem cell factor induces angiogenesis within the brain. Cancer Cell. 2006, 9: 287-300. 10.1016/j.ccr.2006.03.003View ArticlePubMedGoogle Scholar
- Irizarry R, Bolstad B, Collin F, Cope L, Hobbs B, Speed T: Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res. 2003, 31: e15- 10.1093/nar/gng015PubMed CentralView ArticlePubMedGoogle Scholar
- Gautier L, Cope L, Bolstad B, Irizarry R: affy--analysis of Affymetrix GeneChip data at the probe level. Bioinformatics. 2004, 20: 307-315. 10.1093/bioinformatics/btg405View ArticlePubMedGoogle Scholar
- Li C, Wong W: Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection. Proc Natl Acad Sci USA. 2001, 98: 31-36. 10.1073/pnas.011404098PubMed CentralView ArticlePubMedGoogle Scholar
- Smyth G: Limma: linear models for microarray data. Bioinformatics and Computational Biology Solutions using R and Bioconductor. Edited by: Gentleman R, Carey V, Dudoit Irizarry R, Huber W. 2005, New York: Springer.Google Scholar
- Benjamini Y, Hochberg Y: Controlling the false discovery rate: a practical and powerful approach to multiple testing. Journal of the Royal Statistical Society Series B. 1995, 57: 289-300.Google Scholar
- Choe S, Boutros M, Michelson A, Church G, Halfon M: Preferred analysis methods for Affymetrix GeneChips revealed by a wholly defined control dataset. Genome Biol. 2005, 6: R16- 10.1186/gb-2005-6-2-r16PubMed CentralView ArticlePubMedGoogle Scholar
- Subramanian A, Tamayo P, Mootha V, Mukherjee S, Ebert B, Gillette M, Paulovich A, Pomeroy S, Golub T, Lander E, Mesirov J: Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005, 102: 15545-15550. 10.1073/pnas.0506580102PubMed CentralView ArticlePubMedGoogle Scholar
- , : R: A language and environment for statistical computing. 2008, Vienna: R Foundation for Statistical Computing.Google Scholar
- Gentleman R, Carey V, Bates D, Bolstad B, Dettling M, Dudoit S, Ellis B, Gautier L, Ge Y, Gentry J, Hornik K, Hothorn T, Huber W, Iacus S, Irizarry R, Leisch F, Li C, Maechler M, Rossini A, Sawitzki G, Smith C, Smyth G, Tierney L, Yang J, Zhang J: Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 2004, 5: R80- 10.1186/gb-2004-5-10-r80PubMed CentralView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.